Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2018 · 10-Q
Revenue$52.13M$52.13M+49.4% vs Q1 2017 Net Income-$20.72M-$20.72MN/M vs Q1 2017 EPS Diluted-$0.23-$0.23N/M vs Q1 2017 Gross Profit$33,887,000+46.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$16,824,000N/M Free Cash Flowderived-$17,561,000N/M Margins · derivedGross margin65.0%−1.5 pt vs Q1 2017
Operating margin-24.3%+14.0 pt vs Q1 2017
Net margin-39.8%+12.0 pt vs Q1 2017
ended Mar 31, 2018 · filed Apr 26, 2018 · 26 d after period end